This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Vertex's Hep C Drug Needs A Growth Injection

Stocks in this article: VRTX MRK VRUS

CAMBRIDGE, Mass. ( TheStreet) -- Flattening prescription growth for Vertex Pharmaceuticals (VRTX) hepatitis C drug Incivek is causing investors some stress.

I told you last week that Incivek's growth rate was a burning question as we head into third-quarter earnings season. Sure enough, total Incivek scripts for the week ending Sept. 30 were down 2.8% week over week, according to IMS Health. This continues a trend of flat prescription growth that began in August. This chart of total scripts for the past five months tells the tale and explains why Vertex shares shed 9% Monday.

The upper line tracks Incivek total scripts, illustrating quite clearly just how fast the new Hep C drug took off. That's pretty much the definition of a rocket-type drug launch. But all rockets come back to Earth eventually, some sooner than others, so the flattening of the Incivek scrip curve starting in August is what's on the mind of investors these days.

By the way, the bottom line on the charts tracks prescriptions of Merck's (MRK) Hep C drug Victrelis. Notice the narrowing gap between the two lines beginning this summer. Incivek's total market share was 75% or the week ending Sept. 30 compared to 25% for Victrelis, according to IMS. The gap is still wide but it has narrowed from earlier this spring when Incivek's market share was closer to 80%.

Vertex reports third-quarter earnings on Oct. 27. Analysts have Vertex earning 18 cents per share in the third quarter on an adjusted basis, according to Bloomberg.

As for the all-important Incivek, Bloomberg data pegs third-quarter sales consensus at $267 million but that appears to be quite low based on current prescription trends, even with the flattening growth. The Street's whisper number for Incivek sales is closer to $400 million. Incivek sales in the second quarter totaled $75 million.

Vertex has to put up a strong Incivek sales number for the third quarter, but even if they meet or beat consensus by a small margin, investors are going to be asking hard questions about Incivek growth trends moving forward.

The initial Incivek launch was phenomenal, but from where is the next leg of growth going to come?

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,627.82 +270.95 1.56%
S&P 500 2,042.21 +29.32 1.46%
NASDAQ 4,715.7590 +71.4470 1.54%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs